Urology · Bronx, NY
NPI
1912954009
Since 2006
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2940 Grand Concourse, Suite 1a
Bronx, NY, 10458
Phone (718) 684-2516
Groups this clinician bills Medicare through
Medicare paid, 2024
$9,896
254 services
Medicare patients, 2024
52
Average age 73
Drug cost, 2024
$2.5M
5,994 prescriptions
Company payments, 2025
$3,276
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sapan K Polepalle was code 36415 (venipuncture blood collection), 41 times for 33 patients. In total Sapan K Polepalle billed 254 services in 34 codes, and Medicare paid $9,896.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-03-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 41 | 33 | $8.44 | $346 |
| 99213 Office E&M - Established | Office | 38 | 30 | $80.43 | $3,056 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 34 | 28 | $13.85 | $471 |
| 81002 Clinical Chemistry | Office | 33 | 32 | $3.31 | $109 |
| 99214 Office E&M - Established | Office | 13 | 12 | $96.46 | $1,254 |
| 51798 Ultrasound - Nonspecific | Office | 12 | 12 | $9.73 | $117 |
By year: 2022 $28K for 435 services; 2023 $19K for 328 services; 2024 $9,896 for 254 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 41 | 33 | $8.44 | $346 |
| 81002 Clinical Chemistry | 33 | 32 | $3.31 | $109 |
Medicare prescription drug claims, 2024
In 2024, the drug Sapan K Polepalle prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,971 prescriptions and refills. In total Sapan K Polepalle wrote 5,994 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,971 | 3,263 | 482 | $15K |
| Finasteride Generic | 807 | 1,563 | 219 | $4,829 |
| Myrbetriq Mirabegron | 587 | 703 | 108 | $305K |
| Gemtesa Vibegron | 503 | 541 | 107 | $246K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 256 | 318 | 51 | $2,564 |
| Doxazosin Mesylate Generic | 233 | 331 | 49 | $2,273 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 212 | 212 | 148 | $389 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 184 | 184 | 45 | $3,805 |
| Cefuroxime Cefuroxime Axetil | 161 | 161 | 113 | $817 |
| Amoxicillin Generic | 104 | 104 | 96 | $83.03 |
| Xtandi Enzalutamide | 78 | 78 | 11 | $1.1M |
| Cephalexin Generic | 58 | 58 | 51 | $179 |
| Orgovyx Relugolix | 55 | 55 | Under 11 | $152K |
| Amikacin Sulfate Generic | 51 | 51 | 46 | $339 |
| Bicalutamide Generic | 42 | 42 | 24 | $417 |
Brand drugs: - claims; generic drugs: 4,591 claims; opioid claims: 41.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sapan K Polepalle $3,276 ($3,276 in general payments such as food, travel and fees) from 15 companies. The largest payer was Coloplast Corp with $1,622.
| Company | Payments | Amount |
|---|---|---|
| Coloplast Corp | 12 | $1,622 |
| Medtronic, Inc. MDT | 5 | $620 |
| Sumitomo Pharma America, Inc. 4506.T | 15 | $401 |
| Janssen Biotech, Inc. JNJ | 3 | $207 |
| Merck Sharp & Dohme LLC MRK | 1 | $87.42 |
| Teleflex LLC TFX | 4 | $70.31 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $44.04 |
| Endo USA, Inc. | 2 | $35.75 |
| Cycle Pharmaceuticals Inc | 1 | $33.24 |
| Astellas Pharma US Inc 4503.T | 1 | $29.97 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.